Showing results (71-80 of 174) with videos related to

Sort By:
Pageof 18
Plos One|April 13, 2011
Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressorsCristina Cellerai, Alexandre Harari, Hans Stauss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 8, 2011
Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinationsViktor von Wyl, Sabine Yerly, Jürg Böni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 21, 2009
Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in SwitzerlandViktor von Wyl, Sabine Yerly, Philippe Bürgisser, et al.
Plos One|August 1, 2012
Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccineClaire-Anne Siegrist, Christian van Delden, Michael Bel, et al.
Open Forum Infectious Diseases|December 14, 2023
Hepatitis E Virus Infection Epidemiology in Recipients of Allogeneic Hematopoietic Cell TransplantJohan Courjon, Vera Portillo, Sabine Yerly, et al.
Open Forum Infectious Diseases|March 4, 2026
Pretransplant CMV-IgG Titers and DNAemia Are Associated With CMV Infections Post Allogeneic Hematopoietic Cell Transplant With or Without LetermovirLéna Royston, Ming Zou, Federico Simonetta, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2011
Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitorsAlexandra U Scherrer, Viktor von Wyl, Jürg Böni, et al.
Open Forum Infectious Diseases|November 7, 2024
Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV TrialAnnalisa Marinosci, Delphine Sculier, Gilles Wandeler, et al.
Plos One|June 22, 2012
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patientsAlexandra U Scherrer, Bruno Ledergerber, Viktor von Wyl, et al.
The Journal of Infectious Diseases|May 1, 2016
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort StudyAlexandra U Scherrer, Wan-Lin Yang, Roger D Kouyos, et al.
Pageof 18